Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 April 1999Website:
http://seelostherapeutics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 26 Jun 2024 20:20:41 GMTDividend
Analysts recommendations
Institutional Ownership
SEEL Latest News
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis and Spinocerebellar ataxia NEW YORK , Oct. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer's disease at the Society for Neuroscience's Neuroscience 2023 meeting, to be held on November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C.
Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first reported results from its Phase 2 trial of SLS-002 on Wednesday.
Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a treatment for adults with major depressive disorder at risk of suicide, failed to meet its primary goal. The primary goal, or "endpoint," is a key measure used to determine the success of a treatment in clinical trials.
Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatment for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD) but said a too-small sample size means the study did not meet its primary endpoint. Seelos enrolled 147 patients in the Phase 2 trial of SLS-002, intranasal racemic ketamine, below its target for 220 patients, which it blamed on financial constraints.
Results from Part 2 of the phase 2 registration-directed study, using SLS-002 for acute suicidal ideation and behavior for MDD, are expected to be released by Q3 of 2023. The major depressive disorder treatment market is expected to reach $14.96 billion by 2032; Even if only accounting for 58% of MDD patients this is still a huge market. Results from the phase II/III study, using SLS-005 for the treatment of patients with Amyotrophic lateral sclerosis, are expected to be released by Q4 of 2023.
What type of business is Seelos Therapeutics?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
What sector is Seelos Therapeutics in?
Seelos Therapeutics is in the Healthcare sector
What industry is Seelos Therapeutics in?
Seelos Therapeutics is in the Biotechnology industry
What country is Seelos Therapeutics from?
Seelos Therapeutics is headquartered in United States
When did Seelos Therapeutics go public?
Seelos Therapeutics initial public offering (IPO) was on 19 April 1999
What is Seelos Therapeutics website?
https://seelostherapeutics.com
Is Seelos Therapeutics in the S&P 500?
No, Seelos Therapeutics is not included in the S&P 500 index
Is Seelos Therapeutics in the NASDAQ 100?
No, Seelos Therapeutics is not included in the NASDAQ 100 index
Is Seelos Therapeutics in the Dow Jones?
No, Seelos Therapeutics is not included in the Dow Jones index
When does Seelos Therapeutics report earnings?
The next expected earnings date for Seelos Therapeutics is 09 August 2024